Estée Lauder Companies has taken a minority stake in 111Skin, the London-based clinical skincare brand known for luxury serums and treatments targeting visible aging. The investment arrives as Estée Lauder navigates potential merger discussions with Spanish conglomerate Puig, signaling the beauty giant's strategy to expand its prestige skincare portfolio beyond established franchises like Advanced Night Repair and Re-Nutriv.
111Skin specializes in high-performance formulations built around proprietary ingredients like the brand's signature NAC Y2 complex, a combination of N-acetyl carnosine and yeast extract. The brand commands premium price points, with hero products like the Y Shape Contour Serum retailing around $275. Founded in 2011 by Dr. Damian Wyles and Harley Street aesthetician Emma Levy, 111Skin positions itself at the intersection of dermatological science and luxury positioning.
The partnership grants Estée Lauder access to 111Skin's clinical-grade formulation expertise and growing international distribution footprint, particularly in Asia-Pacific markets where the brand has gained traction. For 111Skin, the backing provides resources to accelerate product innovation and expand globally under a partner with unmatched retail relationships and marketing muscle.